Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

OMEROS CORP (OMER)

$9.79 -4.77% NASDAQ: OMER · 15-min delayed
  • SEATTLE, Washington
  • Public · NASDAQ: OMER
  • 175 employees
  • Founded 1994
$708.6MMarket cap
$73.8MRevenue · FY2020
-$3.4MNet income
175Employees
OMERNASDAQ
2009IPO

About OMEROS CORP

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2020
$73.8M
Net income
-$3.4M
Total assets
$325.6M
Market cap
$708.6M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating income
-$122.8M
Income tax
$2.0M
Net income
-$3.4M
EPS (basic)
$-0.05
EPS (diluted)
$-0.05

Balance sheet

Total assets
$325.6M
Current assets
$215.7M
Total liabilities
$446.9M
Current liabilities
$78.1M
Shareholders’ equity
-$121.2M

Cash flow

Operating cash flow
-$116.1M
Investing cash flow
$164.5M
Financing cash flow
-$42.2M
Net cash flow
$6.3M

Statements via Polygon.io (SEC filings)

NASDAQ: OMER
$9.79 -4.77%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.97 $17.18

52-week range

Market cap
$708.6M
EPS (diluted)
$-0.05
Shares outstanding
72.4M
Open
Day range
Prev close
Volume
IPO date
Oct 8, 2009

Omeros Corp (OMER) Stock Price

  • Reported a net loss of $3.4M in FY2020.
  • Trading 43% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review OMEROS CORP.

Write a review
Newsroom

News about OMEROS CORP

News & sentiment via Polygon.io

FAQ

Omeros Corp: frequently asked questions

Is Omeros Corp an American company?

Omeros Corp is a US-based company headquartered in Seattle, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Omeros Corp headquartered?

Omeros Corp is headquartered in Seattle, Washington, United States.

Is Omeros Corp publicly traded?

Yes — Omeros Corp is a publicly traded company. Its stock trades under the ticker symbol OMER on the NASDAQ.

What does Omeros Corp do?

Omeros Corp is an American Pharmaceuticals company in the Health & Beauty sector.

When was Omeros Corp founded?

Omeros Corp was founded in 1994.

Explore

Similar companies

Browse all →